Evidence map›Paper›PMID 37554314›Full record

ArticleCurrent research in parasitology & vector-borne diseases2023

Efficacy of Felpreva®, a new spot-on formulation containing tigolaner, emodepside and praziquantel, applied as a single application to cats artificially infested with ear mites (

Katrin Blazejak, Alta Viljoen, Reinier Zwiegers, Roland Klopper, Hannah Ringeisen, Gabriele Petry, David R Young, Douglas Shane, Jennifer Spruill, Ronald K Tessman and 3 more

Abstract read
In one paragraph

Article in Current research in parasitology & vector-borne diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. The most effective systemic treatment in cats with otodectic mange: A critically appraised topic.The Canadian veterinary journal = La revue veterinaire canadienne · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Katrin BlazejakVetoquinol S.A., 37 Rue de la Victoire, 75009 Paris, France.
Alta ViljoenClinvet International (Pty) Ltd, PO Box 11186, 9321 Universitas, South Africa.
Reinier ZwiegersClinvet International (Pty) Ltd, PO Box 11186, 9321 Universitas, South Africa.
Roland KlopperClindata International (Pty) Ltd, PO Box 11186, 9321 Universitas, South Africa.
Hannah RingeisenElanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, Germany.
Gabriele PetryElanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, Germany.
David R YoungYoung Veterinary Research Services, 3000 Spengler Way, Turlock, CA 95380, USA.
Douglas ShaneYoung Veterinary Research Services, 3000 Spengler Way, Turlock, CA 95380, USA.
Jennifer SpruillYoung Veterinary Research Services, 3000 Spengler Way, Turlock, CA 95380, USA.
Ronald K TessmanElanco Animal Health, 2500 Innovation Way, Greenfield, IN 46140, USA.
Terry SettjeElanco Animal Health, 2500 Innovation Way, Greenfield, IN 46140, USA.
Tanja N KnoppeVet Advice, Dornstücken 25, 22607 Hamburg, Germany.
Norbert MenckeVetoquinol S.A., 37 Rue de la Victoire, 75009 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of Felpreva® (Vetoquinol), a new spot-on application containing the novel acaricide and insecticide tigolaner in combination with emodepside and praziquantel, was evaluated in cats artificially infested with ear mites (

Indexed as

CatEar miteFelpreva®OtoacariosisOtodectes cynotisTigolaner

Identifiers

PMID37554314
PMCPMC10404537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.